Page 2509 - Williams Hematology ( PDFDrive )

2480 Index Index 2481

Plerixafor, 355 Polycythemia (erythrocytosis), 506–510, testosterone treatment-related, 872, 879,
Plethora, 8 871–884. See also Polycythemia 880f
Plg. See Plasminogen (Plg) vera tumors and, 872, 879, 881
PLL. See Prolymphocytic (prolymphoblastic) apparent (relative), 872, 880 spurious, 872, 884
leukemia (PLL) classification, 509–510, 509t, 871–872 stress, 872
Pluripotential stem cell lesion, 1439–1440 clinical features, 506, 508–509, 880–881 therapy, 884
Pluripotential stem cell pool, 1283 consultative approach to, 44–45 Polycythemia hypertonica, 872
PLZF, 230 course and prognosis, 884 Polycythemia vera (PV), 1291–1301
PLZF, 1405 definition and history, 871–872 clinical features, 1293–1295
PMA (phorbol myristate acetate), 1011 differential diagnosis, 882–884, 883f leukemic transformation, 178, 1295
PMF. See Primary myelofibrosis (PMF) epidemiology, 872–873 signs and symptoms, 1293–1294, 1294f
PML (progressive multifocal etiology and pathogenesis, 873–880 spent phase, 1294–1295, 1294f
leukoencephalopathy), 1536 laboratory features, 505f, 881–882 thrombosis and bleeding, 2079–2081
PML (promyelocytic leukemia). See Acute neonatal, 879–880, 881 thrombosis and hemorrhage, 1286,
promyelocytic leukemia (APL) pathophysiology, 506, 508f 1293
PML-RARα primary familial and congenital, 509, 509t, transition to other clonal myeloid
in acute myelogenous leukemia, 1377, 871 diseases, 1280, 1295
1384t Chuvash polycythemia. See Chuvash course and prognosis, 1278t, 1301, 1301f
in acute promyelocytic leukemia, 181, 225, polycythemia definition and history, 1291
230, 240, 1390–1392, 1415 clinical features, 880 differential diagnosis, 1297, 1297t,
PMN (polymorphonuclear neutrophils), 940f definition and history, 871 1449–1450
Pneumococcal polysaccharide vaccine disorders of hypoxia sensing. See epidemiology, 1291
(PPV23), 773 Hypoxia sensing, disorders of etiology and pathogenesis, 1278,
Pneumococcal vaccine (PCV7), 773 epidemiology, 872 1291–1292
Pneumococcus infections, 384. See also etiology and pathogenesis, 873, 873t, chromosomal abnormalities, 178, 179t
Bacterial infections 874f, 877–878 gene mutations
Pneumocystis jiroveci (P. carinii) infections laboratory features, 881 frequency, 1308f
cytomegalovirus infection and, 1268 pheochromocytoma and, 879, 881 JAK2, 228t, 1278, 1308f
in HIV infection, 1239, 1240, 1241t VHL mutations associated with, 510, JAK2 V617F , 178, 1292, 1295–1296,
in hyperimmunoglobulin M syndromes, 876–877, 877f, 878f, 882t 1312f, 1313f
1213 renal, 879–880. See also Renal TET2, 229t, 1292, 1308f
idiopathic CD4+ T lymphocytopenia and, transplantation, erythrocytosis iron deficiency and, 629
1206 following laboratory features, 1295–1296
in immunocompromised host, 384 secondary, 509, 509t, 871–872 blood findings, 1295
prevention, 389, 524, 1115, 1241t, 1514 chemically induced tissue hypoxia and, clonality in female subjects, 1296
in severe combined immunodeficiency 876 erythroid colony cultures, 1296
syndrome, 1218 course and prognosis, 884 erythropoietin levels, 883, 1296
treatment, 386 definition and history, 871–872 JAK2 exon 12 mutations, 1296
PNH. See Paroxysmal nocturnal in Eisenmenger syndrome, 872, 876, JAK2 V617F mutations, 1295–1296
hemoglobinuria (PNH) 881 marrow findings, 1296
Pocked (pitted) red cells, 468 endocrine disorders and, 872, 879, 880f in pregnancy, 125, 2081
Podoplanin, 1870–1871 epidemiology, 872–873 surgical considerations, 1294
Podosomes, 60 erythrocyte enzyme deficiencies and, treatment, 1297–1301, 1298t
POEMS syndrome (osteosclerotic myeloma), 876 erythrocytapheresis, 429t, 432
9, 1733, 1746 etiology and pathogenesis, 874 JAK inhibitors, 341–342
Poikilocytosis, 21, 21f high altitude. See High-altitude plethoric phase, 1297–1300
Poloxamer 188, for sickle cell disease, polycythemia anagrelide, 1300
777t high oxygen-affinity hemoglobins and, aspirin, 1300, 2081
Polyamines, 200 782, 872, 876 epigenetic modulation, 1300
Polyarteritis nodosa, 2106, 2106f laboratory features, 882 interferon, 1299
Polychromatophilic cells, 21 post–renal transplant. See Renal JAK2 inhibitors, 1300
Polychromatophilic erythroblasts, 34, 463f, transplantation, erythrocytosis myelosuppression, 1298–1299
464–465, 465f following phlebotomy, 1299–1300
Polychromatophilic erythrocytes, 34 pulmonary disease and, 872, 881 summary, 1300
Polychromatophilic megaloblasts, 595f sleep apnea-related, 872, 876 symptomatic therapy for pruritus,
Polyclonal hematopoiesis, 83.1012 smoking-related, 872, 876, 876t 1300

Kaushansky_index_p2393-2506.indd 2480 9/21/15 3:22 PM